Chai Discovery builds generative AI foundation models that predict and design protein and antibody structures to accelerate pre-clinical drug discovery.

Clinical-stage biopharmaceutical company developing best-in-disease therapies for vision-threatening eye diseases, including a VEGF/Ang2 bispecific antibody in Phase 3 for DME and wet AMD.